InfoTechTarget and Informa Tech's Digital Businesses Combine.

Together, we power an unparalleled network of 220+ online properties covering 10,000+ granular topics, serving an audience of 50+ million professionals with original, objective content from trusted sources. We help you gain critical insights and make more informed decisions across your business priorities.

AI and Machine Learning in Drug Discovery: Patenting AI-Generated Inventions

Presented by

Craig Humphris (Wrays); Brent Nix (JMIN); Sarah Speight (World IP Review); Frank Landolt, Chief Counsel, Intellectual Property and Legal (Confo Therapeutics).

About this talk

AI and machine learning are shaking up drug discovery, cutting down research timelines, slashing costs, and uncovering new treatment possibilities at an unprecedented pace. Traditional drug development takes over a decade and costs billions, but AI is changing the game- streamlining drug candidate identification, optimising formulations, and improving clinical trial efficiency. However, with AI playing a bigger role in the inventive process, the big question is: who (or what) gets credit for the innovation? Patent laws still require a human inventor, making it tricky to protect AI-generated discoveries. Regulators are starting to tackle the issue, but there’s a lot of uncertainty around how much human involvement is needed to secure a patent. Meanwhile, AI’s influence goes beyond discovery- it’s driving breakthroughs in biomarkers, personalised medicine, and pharma manufacturing. Companies need a strong IP strategy to make sure they stay protected while navigating this evolving legal landscape. This session dives into the latest developments in AI-powered drug discovery, the shifting patent landscape, and what it all means for your IP strategy exploring key themes such as: - AI-Powered Drug Discovery & Patents: How AI is transforming the hunt for new drugs and reshaping IP protection - The Inventorship Dilemma: Can AI be an inventor? How regulators are handling this hot-button issue - Obviousness & Patentability Challenges: Addressing the hurdles of proving AI-generated innovations are truly novel and non-obvious - Smart Patent Strategies for AI Innovations: Securing IP for AI-assisted formulations, biomarkers, and repurposed drugs - Building a Bulletproof IP Strategy: Protecting your AI-driven breakthroughs and staying competitive in the life sciences space Join us for an insightful discussion on the challenges and opportunities AI presents in drug discovery. In this fast-moving field, staying ahead means knowing how to protect what matters.
World Intellectual Property Review Insights

World Intellectual Property Review Insights

15017 subscribers85 talks
Providing insight on Intellectual Property and the Life Sciences
Content for the home of World IP Review and Life Sciences IP Review
Related topics